%0 Case Reports
%T Escalating Oral Treprostinil Dose With Intravenous Treprostinil Bridging Therapy.
%A Perez VC
%A Williams V
%A Rahaghi FF
%J Cureus
%V 16
%N 2
%D 2024 Feb
%M 38500893
暂无%R 10.7759/cureus.54184
%X Oral treprostinil, approved for the treatment of pulmonary arterial hypertension, remains an attractive option in combination with other medications to delay disease progression and improve exercise capacity. However, patients are often challenged with the ability to overcome adverse effects as outpatients and reach effective doses in a timely manner. We describe a case of a 47-year-old female on oral treprostinil who presented to the clinic with worsening symptoms of disease, necessitating higher dosing. This patient was previously uptitrated outpatient with oral treprostinil, which had allowed her to remain stable for years. Once uptitrated with additional intravenous therapy, the oral treprostinil dose was gradually further increased to the new goal dosage, resulting in improvements in symptoms and right ventricular function. This case highlights the versatility of dose optimization of oral treprostinil with rapid bridging through intravenous therapy.